

HLA-Beyond the Basics of A, B, and Dr

Learning Objective 1: Identify the key pathologic findings and management challenges of antibody mediated injury

Learning Objective 2: Describe the main principles and findings in antibody accommodation

Learning Objective 3: Understand the benefits and management implications of post-transplant donor specific antibody screening

1:00pm-5:30pm

Moderators: Elaine Reed, MD, University of Pennsylvania, Philadelphia, PA. Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, Canada.

1:00pm-1:20pm

Antibody Mediated Injury Through the Pathologist's Lens –What Does Suspicious Mean?

Lynn Cornell, MD, Mayo Clinic, Rochester, MN.

1:20pm-1:30pm

Audience Discussion

1:30pm-1:50pm

Antibody Mediated Injury from the Nephrologist's Perspective: Current Dilemmas and Future Directions

Darshana Dadhania, MD, MS, Weill Cornell Medicine, New York City, NY.

1:50pm-2:00pm

Audience Discussion

2:00pm-2:20pm

Accommodation to Antibodies

Elaine Reed, MD, University of Pennsylvania, Philadelphia, PA

2:20pm-2:30pm

Audience Discussion.

2:30pm-2:40pm

Debate-PRO: Monitoring for Donor Specific Antibody on a Routine Basis Is Necessary!

Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, Canada.

2:40pm-2:50pm

Debate-CON: Monitoring for Donor Specific Antibody on a Routine Basis is NOT Necessary!

Howard Gebel, PhD, Emory University, Atlanta, GA.

2:50pm-2:455pm

Debate - PRO: Rebuttal

Peter Nickerson, MD, FRCPC, University of Manitoba, Winnipeg, Canada.

2:55pm-3:00pm

Debate - CON: Rebuttal

Howard Gebel, PhD, Emory University, Atlanta, GA.

3:00pm-3:10pm

Audience Discussion

3:10pm-3:30pm

Coffee Break

3:30pm-3:50pm

Algorithms for Epitope Matching

Vasilis Kosmoliaptis, MD, PhD, University of Cambridge, Cambridge, United Kingdom.

3:50pm-4:00pm

Audience Discussion

4:00pm-4:20pm

Reviewing Available Data on Outcomes

James Cooper, MD, University of Colorado, Aurora, CO.

4:20pm-4:30pm

Audience Discussion

4:30pm-4:50pm

Comprehensive Tour of Non-HLA Antibodies

Matthew Everly, PharmD, Terasaki Research Institute, Los Angeles, CA.

4:50pm-5:00pm

Audience Discussion

5:00pm-5:20pm

Clinical Relevance of Non-HLA Antibodies

Dany Anglicheau, MD, PhD, Necker-Children Malades Hospital, Paris, France.

5:20pm-5:30pm

Audience Discussion